ADAMs (a disintegrin and metalloprotease) comprise a family of cell surface proteins with protease and cell-binding activities. Using different forms and fragments of ADAM12 as substrates in cell adhesion and spreading assays, we demonstrated that alpha9beta1 integrin is the main receptor for ADAM12. However, when alpha9beta1 integrin is not expressed--as in many carcinoma cells--other members of the beta1 integrin family can replace its ligand binding activity. In attachment assays, the recombinant disintegrin domain of ADAM12 only supported alpha9 integrin-dependent tumor cell attachment, whereas full-length ADAM12 supported attachment via alpha9 integrin and other integrin receptors. Cells that attached to full-length ADAM12 in an alpha9 integrin-dependent manner also attached to ADAM12 in which the putative alpha9beta1 integrin-binding motif in the disintegrin domain had been mutated. This attachment was mediated through use of an alternate beta1 integrin. We also found that cell spreading in response to ADAM12 is dependent on the apparent level of integrin activation. Binding of cells to ADAM12 via the alpha9beta1 integrin was Mn(2+)-independent and resulted in attachment of cells with a rounded morphology; attachment of cells with a spread morphology required further activation of the alpha9beta1 integrin. We demonstrated that phosphoinositide-3-kinase appears to be central in regulating alpha9beta1 integrin cell spreading activity in response to ADAM12.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yexcr.2005.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Behçet's syndrome: one year in review 2024.
Clin Exp Rheumatol
October 2024
Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, School of Medicine, and Behçet's Disease Research Centre, Istanbul University-Cerrahpasa, Istanbul, Turkey.
The aim of this review is to provide a critical summary of studies published during 2023 that contribute to our understanding of Behçet's syndrome. An increase in the incidence of BS was reported in Northern Spain after 2014.Studies on patient perspectives showed the impact of Behçet's syndrome on quality of life, daily activities, education, work, and relationships.
View Article and Find Full Text PDFα9β1 integrin & its ligands as new potential biomarkers in FMF.
Indian J Med Res
July 2024
Department of Medical Pharmacology, Bursa Uludag University Faculty of Medicine, Nilufer-Bursa, Turkey.
Article Synopsis
- Familial Mediterranean Fever (FMF) is a hereditary illness that causes fever, stomach pain, and joint swelling, and colchicine is the main treatment but doesn’t cure it.
- In a study, they looked at blood samples from 50 people, including healthy individuals and those with active or inactive FMF, to measure certain markers tied to the disease.
- The results showed that some markers were higher in patients having FMF attacks compared to healthy people and those in remission, suggesting these markers could help in finding new ways to diagnose and treat FMF.
Genetic ablation of myeloid integrin α9 attenuates early atherosclerosis.
J Leukoc Biol
November 2024
Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, 3160 Medical Labs, Iowa City, IA 52242, United States.
Article Synopsis
- Integrin α9β1 plays a crucial role in helping leukocytes stick to blood vessel linings, which is significant in the context of atherosclerosis.
- In experiments with mice lacking myeloid cell-specific α9β1, researchers found that these mice had fewer early signs of atherosclerosis compared to their counterparts, indicating a protective effect.
- This reduction in atherosclerosis was linked to lower levels of neutrophils and their associated inflammatory traps in the blood vessels, suggesting that disabling α9β1 helps to limit excessive immune responses.
Universal cell membrane camouflaged nano-prodrugs with right-side-out orientation adapting for positive pathological vascular remodeling in atherosclerosis.
Chem Sci
May 2024
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University Chongqing 400030 China
A right-side-out orientated self-assembly of cell membrane-camouflaged nanotherapeutics is crucial for ensuring their biological functionality inherited from the source cells. In this study, a universal and spontaneous right-side-out coupling-driven ROS-responsive nanotherapeutic approach, based on the intrinsic affinity between phosphatidylserine (PS) on the inner leaflet and PS-targeted peptide modified nanoparticles, has been developed to target foam cells in atherosclerotic plaques. Considering the increased osteopontin (OPN) secretion from foam cells in plaques, a bioengineered cell membrane (OEM) with an overexpression of integrin α9β1 is integrated with ROS-cleavable prodrugs, OEM-coated ETBNPs (OEM-ETBNPs), to enhance targeted drug delivery and on-demand drug release in the local lesion of atherosclerosis.
View Article and Find Full Text PDFInteractions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT.
Blood Adv
May 2024
Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA.
Venous thromboembolic events are significant contributors to morbidity and mortality in patients with stroke. Neutrophils are among the first cells in the blood to respond to stroke and are known to promote deep vein thrombosis (DVT). Integrin α9 is a transmembrane glycoprotein highly expressed on neutrophils and stabilizes neutrophil adhesion to activated endothelium via vascular cell adhesion molecule 1 (VCAM-1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!